DBV Technologies reported $7.5M in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amarin USD 0 0 Mar/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
DBV Technologies USD 7.5M 1.4M Sep/2026
Galectin Therapeutics USD 71.74M 10.6M Dec/2023
Halozyme Therapeutics USD 2.15B 2.02M Jun/2026
Incyte USD 38.27M 1.16M Jun/2026
Insmed USD 544.86M 180.93M Sep/2026
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
United Therapeutics USD 200M 100M Mar/2025